ORCL
Oracle Corporation
ORCL has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ORCL overall, supported by stronger fundamentals.
ORCL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Weak | |
| Strong |
ORCL's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ORCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 15x | $127 | — |
| Cheap | 19x | $119 | -6.8% |
| Current | 20x | $127 | — |
| Fair | 30x | $189 | +49% |
| Expensive | 39x | $247 | +94% |
Historical ranges are pointers, not guarantees.
ORCL's PE is in its cheap range at 20x. If earnings grow as analysts expect, today's price would be 15x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ORCL in the historical PE scenario, which offers more potential upside but is not a forecast.
ORCL Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| High |
Analysts expect strong earnings and revenue growth for ORCL, but weaker profitability.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over ORCL on the outlook, with more favorable profitability expectations.
ORCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.53 | +34% |
| Q3 2026 | $6.38 | +48% |
| Q2 2026 | $5.83 | +34% |
| Q1 2026 | $5.57 | +31% |
| Q4 2025 | $5.32 | +30% |
| Q3 2025 | $4.32 | +11% |
| Q2 2025 | $4.34 | +17% |
| Q1 2025 | $4.26 | +12% |
| Q4 2024 | $4.09 | +13% |
ORCL has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ORCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.3B | +30% |
| Q2 2026 | $19.2B | +21% |
| Q1 2026 | $17.2B | +22% |
| Q4 2025 | $16.1B | +14% |
| Q3 2025 | $14.9B | +12% |
| Q2 2025 | $15.9B | +11% |
| Q1 2025 | $14.1B | +6.4% |
| Q4 2024 | $14.1B | +8.6% |
ORCL's revenue has grown year over year for 13 quarters in a row: $19.3B last quarter, up 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 35% | +6.1 points |
| Q2 2026 | 32% | -0.2 points |
| Q1 2026 | 32% | +0.9 points |
| Q4 2025 | 29% | -0.6 points |
| Q3 2025 | 29% | -1.3 points |
| Q2 2025 | 32% | -0.7 points |
| Q1 2025 | 31% | +2.6 points |
| Q4 2024 | 30% | +2 points |
ORCL has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ORCL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ORCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5.4B | -$5B |
| Q2 2026 | -$1.9B | +$1.1B |
| Q1 2026 | -$11.5B | -16275% |
| Q4 2025 | -$10B | -$7.3B |
| Q3 2025 | -$362M | -107% |
| Q2 2025 | -$2.9B | -189% |
| Q1 2025 | $71M | -98% |
| Q4 2024 | -$2.7B | -$1.7B |
ORCL has burned cash in seven of the last eight quarters: −$28.7B over the past year, against −$5.9B the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ORCL on cash generation, producing positive trailing cash flow while its opponent burns cash.
ORCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3% | +86M shares |
| 1 year | +3.1% | +91M shares |
| 3 years | +6.3% | +177M shares |
| 5 years | +4.9% | +139M shares |
| Available history | -9.9% | -331M shares |
ORCL has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $95M |
| Q2 2025 | $150M |
| Q1 2025 | $150M |
| Q4 2024 | $150M |
| Q3 2024 | $150M |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ORCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.9x | Net Cash |
| Q2 2026 | 3.5x | Elevated |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 0.3x | Very low |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 0.2x | Very low |
| Q4 2024 | 0.2x | Very low |
ORCL has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ORCL on leverage, with a lower net debt burden relative to earnings.
ORCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 41.9 | Neutral |
| Stochastic | 23.0 | Neutral |
ORCL's weekly RSI is 42 (neutral) and its Stochastic is 23 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ORCL PE vs Technology Sector
| Metric | ORCL | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 28% below |
| PE % | 28 | 35 | 7 pts below |
ORCL is trading at 20x earnings, a 28% discount to the Technology sector's median of 28x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ORCL on valuation relative to its sector.
ORCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $131.1 | 3.1% below |
| 20 week MA | $137.6 | 7.7% below |
| 50 week MA | $160.3 | 21% below |
| 100 week MA | $181.4 | 30% below |
| 200 week MA | $151.9 | 16% below |
ORCL is in a downtrend: it's below all five of its weekly moving averages, and 16% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ORCL on trend strength, trading above more of its moving averages.
ORCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $53.5 | $65.0 | +22% |
| 2021 | $65.0 | $89.7 | +38% |
| 2022 | $89.7 | $80.9 | -9.9% |
| 2023 | $80.9 | $105.4 | +30% |
| 2024 | $105.4 | $169.0 | +60% |
| 2025 | $169.0 | $198.0 | +17% |
| 2026 YTD | $198.0 | $127.1 | -36% |
ORCL is down 36% so far in 2026, after finishing higher in five of the previous six years.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ORCL on returns for 2026, with the stronger performance.